Fairvalue-Calculator Fairvalue-Calculator
EN DE

SEP Analytical (Shanghai) Co (301228) Fair Value & Analysis

Technology · CN · Market cap 9.3B CNY

Price¥75.90
Fair Value¥15.31
Upside-79.8%
Quality94/100
Evidence: Low Range ¥11.48 – ¥19.13

Analysis

SEP Analytical (Shanghai) Co (301228) currently trades at ¥75.90, while our model-based Fair Value estimate is ¥15.31 — implying the stock looks roughly 79.8% overvalued today. We read business quality at 94/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

SEP Analytical (Shanghai) Co., Ltd. engages in the provision of third-party testing services in China. It offers soil, ground water and wastewater, seawater, solid waste, sludge, edible agricultural products, food, cosmetics, textiles, toys and children's products, occupational health, medicine, and other testing services related to human health. The company is also involved in the provision of investigation and consulting, online monitoring operation and maintenance, well drilling, repairing, intelligent monitoring, comprehensive turnkey package, and other technical services. It serves the governments, as well as consulting agencies, engineering companies, and end customers. The company was founded in 2008 and is headquartered in Shanghai, China.

Open the full interactive analysis →

Similar stocks

Keyence Corporation (KYCCF) -51% Keysight Technologies, Inc (KEYS) -75% Garmin Ltd (GRMN) -31% Chroma ATE Inc (2360) -85% Teledyne Technologies Incorporated (TDY) -37% Hexagon AB (HXGBF) -41%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.